Lycia Therapeutics, Inc. has filed an Amended and Restated Certificate of Incorporation (Charter) and Amended and Restated Bylaws with the Secretary of State of Delaware. The documents became effective on October 26, 2026, in connection with the closing of the company’s initial public offering (IPO).
The filing indicates that the board of directors and stockholders previously approved the amendment and restatement of these documents to be effective immediately prior to the closing of the Offering. The company’s common stock, which has a par value of $0.0001 per share, trades under the symbol LYCA on The Nasdaq Global Select Market.
According to the filing, a detailed description of the provisions within the Charter and Bylaws is included in the section titled “Description of Capital Stock” within the final prospectus dated October 22, 2026. This prospectus relates to a Registration Statement on Form S-1 (File No. 333-299300) filed with the Securities and Exchange Commission.
The filing also references the exhibits attached to the report, which include the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and the Amended and Restated Bylaws (Exhibit 3.2).
